Evidence-Based
Management of Subarachnoid Hemorrhage
Michael Diringer, M.D. -- Professor
of Neurology, Neurological Surgery, and Occupational Therapy
Washington University School of Medicine -- Presented July
26, 2005
Mg
Placebo
Primary outcome
DCI (On-treatment )
0.66 (0.38–1.14)
14 (35 NNTH to 6 NNTB)
Secondary outcomes
New hypodensities on CT*
1.04 (0.79–1.37)
Poor outcome (ITT)
0.77 (0.54–1.09)
12 (37 NNTH to 5 NNTB)
Excellent outcome (ITT)
3.4 (1.3–8.9)
11 (7 NNTB to 43 NNTB)
This study suggests that magnesium reduces DCI and subsequent poor outcome,
but the results are not yet definitive. A next step should be a phase III trial to confirm
the beneficial effect of magnesium therapy, with poor outcome as primary outcome.
